BMJ, doi: 10.1136/bmj.39266.425069.AD, (Published 11 July 2007)

Research

Main morbidities recorded in the women's international study of long duration oestrogen after menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women

¹ MRC General Practice Research Framework, Stephenson House, London NW1 2ND, ² University of Adelaide, Women's and Children's Hospital, Adelaide SA 5006, Australia, ³ Department of Primary Health Care and General Practice, Wellington School of Medicine and Health Sciences, New Zealand, ⁴ MRC Clinical Trials Unit, London NW1 2DA, ⁵ Department of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London WC1E 7HT

Objective To assess the long term risks and benefits of hormone replacement therapy (combined hormone therapy versus placebo, and oestrogen alone versus combined hormone therapy).

Design Multicentre, randomised, placebo controlled, double blind trial.

Setting General practices in UK (384), Australia (91), and New Zealand (24).

Participants Postmenopausal women aged 50-69 years at randomisation. At early closure of the trial, 56 583 had been screened, 8980 entered run-in, and 5692 (26% of target of 22 300) started treatment.

Interventions Oestrogen only therapy (conjugated equine oestrogens 0.625 mg orally daily) or combined hormone therapy (conjugated equine oestrogens plus medroxyprogesterone acetate 2.5/5.0 mg orally daily). Ten years of treatment planned.

Main outcome measures Primary outcomes: major cardiovascular disease, osteoporotic fractures, and breast cancer. Secondary outcomes: other cancers, death from all causes, venous thromboembolism, cerebrovascular disease, dementia, and quality of life.

Results The trial was prematurely closed during recruitment, after a median follow-up of 11.9 months (interquartile range 7.1-19.6, total 6498 women years) in those enrolled, after the publication of early results from the women's health initiative study. The mean age of randomised women was 62.8 (SD 4.8) years. When combined hormone therapy (n=2196) was compared with placebo (n=2189), there was a significant increase in the number of major cardiovascular events (7 v 0, P=0.016) and venous thromboembolisms (22 v 3, hazard ratio 7.36 (95% CI 2.20 to 24.60)). There were no statistically significant differences in numbers of breast or other cancers (22 v 25, hazard ratio 0.88 (0.49 to 1.56)), cerebrovascular events (14 v 19, 0.73 (0.37 to 1.46)), fractures (40 v 58, 0.69 (0.46 to 1.03)), and overall deaths (8 v 5, 1.60 (0.52 to 4.89)). Comparison of combined hormone therapy (n=815) versus oestrogen therapy (n=826) outcomes revealed no significant differences.

Conclusions Hormone replacement therapy increases cardiovascular and thromboembolic risk when started many years after the menopause. The results are consistent with the findings of the women's health initiative study and secondary prevention studies. Research is needed to assess the long term risks and benefits of starting hormone replacement therapy near the menopause, when the effect may be different.

Trial registration Current Controlled Trials ISRCTN 63718836

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

Related Articles

Questioning fondly held assumptions

Jane Smith
BMJ 2007 335: 0. [Extract] [Full Text]

Hormone replacement therapy comes full circle

Helen Roberts
BMJ 2007 335: 219-220. [Extract] [Full Text] [PDF]

Changes in use of hormone replacement therapy after the report from the Women's Health Initiative: cross sectional survey of users

Beverley Lawton, Sally Rose, Deborah McLeod, and Anthony Dowell
BMJ 2003 327: 845-846. [Full Text] [PDF]

This article has been cited by other articles:

• Sare, G. M., Gray, L. J., Bath, P. M.W. (2008). Association between hormone replacement therapy and subsequent arterial and venous vascular events: a meta-analysis. Eur Heart J 0: ehn299v1-11 [Abstract] [Full text]  
• Konhilas, J. P., Leinwand, L. A. (2007). The Effects of Biological Sex and Diet on the Development of Heart Failure. Circulation 116: 2747-2759 [Full text]  
• (2007). International Study Supports Conventional WISDOM About Hormone Therapy. Journal Watch Cardiology 2007: 3-3 [Full text]  
• Roberts, H. (2007). Hormone replacement therapy comes full circle. BMJ 335: 219-220 [Full text]  

Rapid Responses:

Read all Rapid Responses

WISDOM, starting age of HRT and vascular risks

Ellen C G Grant
bmj.com, 13 Jul 2007 [Full text]

HRT user - early menopause

Nina Kathleen Edge
bmj.com, 14 Jul 2007 [Full text]

Combined OCs and HRTs have similar effects, including increased risks of thrombosis and heart attacks.

Ellen C G Grant
bmj.com, 18 Jul 2007 [Full text]

Long Term HRT and its risks

Maria Louise O Demesa
bmj.com, 18 Jul 2007 [Full text]

Chronomics: Cardiovascular disease risk of hormonal replacement therapy related to decreased heart rate variability?

Germaine Cornelissen, et al.
bmj.com, 29 Jul 2007 [Full text]

Hormone replacement therapy and information: in Italy a Consensus Conference to help woman decision

Paola Mosconi, et al.
bmj.com, 4 Aug 2007 [Full text]

Estrogen alone is unethical and is also unethical to include the women with potential risk factors to the cardiovascular events in the trial with the HRT drugs

Neeru Gupta, et al.
bmj.com, 24 Aug 2007 [Full text]

WISDOM Trial, Postmenopausal Hormone Replacement and Cardiovascular Events: Why it is still not wise to use equine estrogens

Matthias Barton, et al.
bmj.com, 28 Aug 2007 [Full text]